ZCM
MYGN icon

Ziegler Capital Management’s Myriad Genetics MYGN Stock Holding History

Ziegler Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-57,274
Closed -$820K – 483
2020
Q1 		$820K Buy
+57,274
New +$1.21M 0.02% 391

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ziegler Capital Management's MYGN Position: Q2 2020 in Review

Ziegler Capital Management sold out of Myriad Genetics (MYGN) in Q2 2020, closing a stake of 57,274 shares — an estimated $820K sold.

Ziegler Capital Management first reported a position in MYGN in Q1 2020 and held it in 1 quarter. The position peaked at $820K in Q1 2020. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2020.

  • Ziegler Capital Management reported no remaining Myriad Genetics position as of Q2 2020 after selling out during the quarter.
  • Ziegler Capital Management sold 57,274 Myriad Genetics shares in Q2 2020, an estimated $820K.
  • Ziegler Capital Management first reported a position in Myriad Genetics in Q1 2020 and held it in 1 quarter.
  • Ziegler Capital Management's Myriad Genetics position peaked at $820K in Q1 2020.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2020.

Based on Ziegler Capital Management's 13F filing for Q2 2020, filed 24 Jul 2020.